BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...target degrons — the glycine loop structures that thalidomide...
BioCentury | Oct 1, 2020
Politics, Policy & Law

Revlimid, Copaxone are poster children for price abuses, House committee says

...whether to implement a REMS program for Thalomid...
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...degraders that make broader use of the “degron” structures grabbed by the field’s first drugs, thalidomide...
BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

...degraders that make broader use of the “degron” structures grabbed by the field’s first drugs, thalidomide...
...role. The company is going after targets containing degrons -- the glycine loop structures that thalidomide...
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

...targeting chimeras because they are easier to rationally design. In contrast, molecular glue therapies like thalidomide...
BioCentury | Mar 3, 2020
Product Development

Following Phase III readout, Karyopharm seeks approval of Xpovio for second-line MM

...CASTOR and the OPTIMISMM Phase III studies” of anti-CD38 mAb Darzalex daratumumab plus Vd and thalidomide...
...A/S Genmab A/S (CSE:GMAB; NASDAQ:GMAB) and Johnson & Johnson (NYSE:JNJ) is approved in combination with thalidomide...
BioCentury | Dec 13, 2019
Company News

Novartis gains CHMP support for Eylea competitor in wet AMD

...anti-CD-38 mAb from the Janssen-Cilag International NV unit of Johnson & Johnson (NYSE:JNJ), with bortezomib, thalidomide...
BioCentury | Nov 7, 2019
Targets & Mechanisms

New cereblon substrates linked to thalidomide teratogenicity

...new thalidomide-dependent CRBN substrates that could be applied to screens for new, safer thalidomide derivatives. Thalidomide...
...Thalidomide was banned in the 1960s before gaining approval for multiple myeloma in 1998 as Thalomid...
...4 TP63 (p63) - Tumor protein p63 Inhua Muijrers-Chen, Associate Editor Thalomid, thalidomide (Actimid, CDC 394, Synovir, Thalidomide Celgene, Thalidomide Pharmion) Avadomide...
BioCentury | Oct 17, 2019
Company News

Plexium debuts with $28M, aims to induce protein degradation by searching all possibilities

...Neotribe Ventures. Companies have been interested in developing E3 ligase modulators since the discovery that thalidomide...
BioCentury | Jun 14, 2019
Company News

Tessa forms JV with biohub to bring its cell therapies to China

...in China" ). Hongjiang Li, Staff Writer Kymriah, tisagenlecleucel (CTL019, cart-19, tisagenlecleucel-t) Thalomid, thalidomide (Actimid, CDC 394, Synovir, Thalidomide Celgene, Thalidomide Pharmion) Cellular...
Items per page:
1 - 10 of 915